Antibodies binding to fibrin and pharmaceutical compositions containing the same
By designing humanized antibodies with specific amino acid sequences to bind with high affinity to insoluble fibrin, and connecting them to cytotoxic agents through linkers designed at plasmin cleavage sites, an ADC is formed, which solves the problem of insufficient antibody binding strength and achieves targeted cancer treatment with reduced side effects.
Patent Information
- Application Number
- CN202180025986.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-03-30
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2041-03-30
AI Technical Summary
In existing technologies, the binding strength between antibodies and fibrin is insufficient, making them difficult to use effectively for cancer treatment and in vivo imaging.
Humanized antibodies with variable regions of heavy and light chains containing specific amino acid sequences were developed. These antibodies bind to insoluble fibrin with a stronger affinity than fibrinogen and are linked to cytotoxic agents via linkers designed with plasmin cleavage sites to form antibody-drug conjugates (ADCs) that target cancer sites to release cytotoxic agents.
It achieves high affinity binding of antibodies to insoluble fibrin, improving the effectiveness of cancer treatment, and reduces side effects on normal tissues through site-specific release of cytotoxic agents.
Smart Images

Figure HDA0003871565290000011 
Figure HDA0003871565290000021 
Figure HDA0003871565290000031
Abstract
Description
Technical Field
[0001] The present invention relates to an antibody binding to fibrin and a pharmaceutical composition containing the antibody. Background Art
[0002] Antibodies that bind to fibrin with a stronger affinity than to fibrinogen have been developed (Patent Documents 1 and 2). These patent documents disclose the use of the antibodies for cancer treatment. Antibodies that strongly bind to fibrin can also be used for in vivo imaging (Patent Documents 1 and 2).
[0003] Prior art literature
[0004] Patent Literature
[0005] Patent Document 1: WO2014 / 133093
[0006] Patent Document 2: WO2018 / 203517 Summary of the invention
[0007] The present invention provides an antibody that binds to fibrin and a pharmaceutical composition containing the antibody. The present invention particularly provides a humanized antibody that binds to fibrin and a pharmaceutical composition containing the antibody.
[0008] According to the present invention, the following inventions can be provided.
[0009] [1] An antibody or an antigen-binding fragment thereof that binds to insoluble fibrin, comprising:
[0010] (1) a heavy chain variable region comprising a heavy chain CDR1 having the amino acid sequence set forth in SEQ ID NO: 1, a heavy chain CDR2 having the amino acid sequence set forth in SEQ ID NO: 2, and a heavy chain CDR3 having the amino acid sequence set forth in SEQ ID NO: 3, and
[0011] A light chain variable region comprising a light chain CDR1 having the amino acid sequence set forth in SEQ ID NO: 4, a light chain CDR2 having the amino acid sequence set forth in SEQ ID NO: 5, and a light chain CDR3 having the amino acid sequence set forth in SEQ ID NO: 6; or
[0012] (2) a heavy chain variable region comprising a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 9, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 10, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 11, and
[0013] A light chain variable region comprising a light chain CDR1 having the amino acid sequence set forth in SEQ ID NO:12, a light chain CDR2 having the amino acid sequence set forth in SEQ ID NO:13, and a light chain CDR3 having the amino acid sequence set forth in SEQ ID NO:14.
[0014] [2] An antibody or an antigen-binding fragment thereof that binds to insoluble fibrin, which is an insoluble fibrin antibody or an antigen-binding fragment thereof, comprising:
[0015] (3) a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 7 and a light chain variable region having the amino acid sequence set forth in SEQ ID NO: 8; or
[0016] (4) A heavy chain variable region having the amino acid sequence described in SEQ ID NO: 15 and a light chain variable region having the amino acid sequence described in SEQ ID NO: 16.
[0017] [3] The antibody or antigen-binding fragment thereof that binds to insoluble fibrin according to [1] or [2] above, which binds to insoluble fibrin with a stronger affinity than its affinity for fibrinogen; or
[0018] Binds to insoluble fibrin with a stronger affinity than to fibrinogen and
[0019] (5) comprising: a heavy chain variable region having an amino acid sequence that is 90% or more identical to the heavy chain variable region of the antibody described in any one of (1) to (4) above, and a light chain variable region of the antibody;
[0020] (6) comprising: a heavy chain variable region of the antibody described in any one of (1) to (4) above, and a light chain variable region having an amino acid sequence that is 90% or more identical to the light chain variable region of the antibody;
[0021] (7) comprising: a heavy chain variable region having an amino acid sequence that is 90% or more identical to the heavy chain variable region of the antibody described in any one of (1) to (4) above, and a light chain variable region having an amino acid sequence that is 90% or more identical to the light chain variable region of the antibody;
[0022] (8) comprising: a heavy chain variable region having an amino acid sequence that is 95% or more identical to the heavy chain variable region of the antibody described in any one of (1) to (4) above, and a light chain variable region of the antibody;
[0023] (9) comprising: a heavy chain variable region of the antibody described in any one of (1) to (4) above, and a light chain variable region having an amino acid sequence that is 95% or more identical to the light chain variable region of the antibody; or
[0024] (10) comprising: a heavy chain variable region having an amino acid sequence that is 95% or more identical to the heavy chain variable region of the antibody described in any one of (1) to (4) above, and a light chain variable region having an amino acid sequence that is 95% or more identical to the light chain variable region of the antibody.
[0025] [4] The antibody or antigen-binding fragment thereof according to any one of [1] to [3] above, which is a humanized antibody or antigen-binding fragment thereof.
[0026] [5] An antibody-drug conjugate comprising the antibody or antigen-binding fragment thereof according to any one of [1] to [4] above.
[0027] [6] A pharmaceutical composition comprising the antibody-drug conjugate described in [5] above.
[0028] [7] The pharmaceutical composition according to [6] above, which is used for treating cancer.
[0029] [8] A pharmaceutical composition for treating cancer, comprising an anticancer agent containing the antibody or antigen-binding fragment thereof according to any one of [1] to [4] above.
[0030] [9] An in vivo diagnostic agent comprising the antibody or antigen-binding fragment thereof according to any one of [1] to [4] above. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1 The results of ELISA experiments showing the binding of humanized antibody 99 and humanized antibody 1101 to various antigens are shown. BSA indicates bovine serum albumin, FNG indicates fibrinogen, SF indicates soluble fibrin, FDP indicates fibrin degradation product, and IF indicates insoluble fibrin.
[0032] Figure 2 The results of Western blotting showing the reactivity of antibodies to denatured fibrinogen (1 μg / lane) are shown. Denatured fibrinogen was subjected to SDS-PAGE and transferred to a filter membrane, and then various antibodies at the indicated concentrations were reacted with the filter membrane. Denatured fibrinogen has a characteristic structure of insoluble fibrin, i.e., a structure to which humanized 99 antibody and 1101 antibody bind (a structure not possessed by non-denatured fibrinogen).
[0033] Figure 3 Shown are hematoxylin and eosin-stained images of pancreatic tissue sections of HE-PKC mice (upper panel) and immunochemical staining images of pancreatic tissue sections obtained using humanized 1101 antibody and humanized 99 antibody (lower four panels).
[0034] Figure 4 The figures show immunochemical staining images of thrombi incidentally found in blood vessels of normal tissue sections of human lung cancer resection specimens using humanized 1101 antibody and humanized 99 antibody.
[0035] Figure 5These are the results of measuring the particle sizes (nm) of humanized 99 antibody and humanized 1101 antibody expressed in Chinese hamster ovary cells (CHO cells) using Deluxanano (trademark). DETAILED DESCRIPTION
[0036] In the present specification, the "subject" is a mammal, for example, a dog, a cat, a cow, a horse, a pig, a primate (for example, a monkey, a gorilla, an orangutan, a bonobo, a chimpanzee, and a human), for example, a human.
[0037] In this specification, "treatment" is used to include treatment (therapeutic treatment) and prevention (preventive treatment). In this specification, "treatment" refers to the treatment, cure, prevention or mitigation of disease or injury, or the slowing down of the development rate of disease or injury. In this specification, "prevention" refers to reducing the possibility of disease or disease occurrence, or delaying the occurrence of disease or disease.
[0038] In this specification, "disease" refers to a condition for which treatment is beneficial. In this specification, "cancer" refers to a malignant tumor.
[0039] In this specification, "therapeutically effective amount" refers to the amount of drug that is effective for treating (preventing or treating) a disease or condition. A therapeutically effective amount of a drug can reduce the rate of deterioration of symptoms of a disease or condition, prevent the deterioration of the above symptoms, improve the above symptoms, cure the above symptoms, or inhibit the occurrence or development of the above symptoms.
[0040] In this specification, "fibrin" refers to an insoluble coagulation formed by cleavage of the C-termini of the three polypeptide chains (Aα chain, Bβ chain and γ chain) constituting fibrinogen. In this specification, fibrin is sometimes referred to as insoluble fibrin. More specifically, the C-terminus of fibrinogen is cleaved to form a state called a fibrin monomer, and the fibrin monomer polymerizes under the action of calcium to form a poorly soluble fibrin polymer. The fibrin polymer is cross-linked between polymers under the action of factor XIII to form stabilized fibrin (insoluble fibrin or fibrin gel defined in this specification). Insoluble fibrin can be decomposed by plasmin. Plasmin is contained in plasma in the form of plasminogen as a precursor. When the peptide between Arg-Val of plasminogen is decomposed by plasminogen activators (such as urokinase, tissue plasminogen activator and streptokinase), plasminogen produces plasmin. Plasmin can be inhibited by proteins called plasmin inhibitors to limit its action.
[0041] The Aα chain of fibrinogen may be the Aα chain of human fibrinogen. Examples of the Aα chain of human fibrinogen include the Aα chain of human fibrinogen having an amino acid sequence registered as GenBank Accession No. AAI01936.1 and the Aα chain of human fibrinogen having an amino acid sequence corresponding to the amino acid sequence.
[0042] The Bβ chain of fibrinogen may be the Bβ chain of human fibrinogen. Examples of the Bβ chain of human fibrinogen include the Bβ chain of human fibrinogen having an amino acid sequence registered as NCBI Reference No. NP_005132.2 and the Bβ chain of human fibrinogen having an amino acid sequence corresponding to the amino acid sequence.
[0043] The fibrinogen γ chain may be a human fibrinogen γ chain. Examples of the human fibrinogen γ chain include a human fibrinogen γ chain having an amino acid sequence registered as GenBank Accession No. AAH07044.1 and a human fibrinogen γ chain having an amino acid sequence corresponding to the amino acid sequence.
[0044] In this specification, "antibody" refers to immunoglobulin. Antibodies can be various isotype antibodies, for example, IgG. Antibodies can be preferably monoclonal antibodies. Antibodies can be human chimeric antibodies, humanized antibodies or human antibodies. Human chimeric antibodies can be prepared by replacing the constant region of a non-human antibody with the constant region of a human antibody. Humanized antibodies can be prepared by replacing the 6 CDRs of a human antibody with the 6 corresponding CDRs of a non-human antibody. Human antibodies can be prepared using animals (such as mice) obtained by replacing at least the heavy chain variable region of an immunoglobulin with the corresponding region of a human locus. When the constant region is non-human, human antibodies can be obtained by replacing the constant region with the amino acid sequence of a human antibody. In this specification, antibodies can be preferably humanized antibodies. In this specification, antibodies can be preferably human antibodies. Antibodies have a signal peptide when they are produced in cells, but when they are secreted outside the cells, the signal peptide is removed. Therefore, when administered as a drug, antibodies do not require a signal peptide.
[0045] In this specification, "CDR" refers to the complementary determining region present in the heavy chain variable region and the light chain variable region of an antibody. There are three CDRs in each of the heavy chain and light chain variable regions, which are referred to as CDR1, CDR2, and CDR3 from the N-terminus. CDRs can be determined, for example, based on the numbering of Kabat et al. (Kabat, EA et al., Sequences of Proteins of Immunological Interest, 5th ed., 1991, Bethesda: US Dept. of Health and Human Services, PHS, NIH.).
[0046] In this specification, "insoluble fibrin-specific antibody" refers to an antibody that binds to insoluble fibrin and has a higher affinity for insoluble fibrin than for fibrinogen. Such insoluble fibrin-specific antibody can be easily obtained by screening for affinity for insoluble fibrin and affinity for fibrinogen. Fibrin has an epitope site that is exposed only after the three-dimensional structure changes in insoluble fibrin and becomes insoluble. Therefore, "insoluble fibrin-specific antibody" can be obtained by immunizing with the exposed domain, i.e., the D domain (hereinafter also referred to as "D-domain") as an immunogen. In addition, it can also be obtained using linear peptides. For example, when a partial peptide of the fibrin B β chain at positions 231 to 246 of the amino acid sequence corresponding to the fibrin B β chain (for example, the human fibrin B β chain may have the amino acid sequence shown in sequence number 17) is used for immunization, an "insoluble fibrin-specific antibody" can be obtained. In addition, "insoluble fibrin-specific antibodies" can also be obtained by immunizing with a peptide consisting of the amino acid sequence recorded in sequence number 18 as an immunogen. Such an insoluble fibrin-specific antibody can be an antibody with a higher affinity for insoluble fibrin than for any one of fibrinogen, fibrin monomer and fibrin polymer. As an insoluble fibrin-specific antibody, an antibody can be obtained whose affinity for insoluble fibrin to affinity for fibrinogen is, for example, more than 1.5, more than 2, more than 3, more than 4 or more than 5, which is greater than 1. Affinity refers to binding affinity (KD), which can be determined by known methods such as ELISA, Kinetic Exclusion Assay, etc. In this specification, strong affinity means that KD is low. In this specification, weak affinity means that KD is high.
[0047] In this specification, "competition" refers to competing with other binding antibodies for the combination of an antigen. Competition can occur when the binding sites of two antibodies overlap for a certain antigen. Such an antibody can be obtained by immunization using an epitope as described above, and / or can be obtained by utilizing a competition test to confirm whether the combination of an antibody and an antigen is reduced due to another antibody. As antibodies that compete, antibodies that compete with each other can be cited.
[0048] In this specification, "antibody-drug conjugate" (hereinafter also referred to as "ADC") refers to a substance formed by connecting an antibody to a cytotoxic agent. ADC can connect an antibody to a cytotoxic agent through a suitable linker. As a cytotoxic agent, chemotherapeutic drugs, radioactive isotopes and toxins can be used. ADC also includes a conjugate of an antigen-binding fragment of an antibody and a drug.
[0049] In this specification, "antigen-binding fragment of an antibody" refers to a fragment of an antibody that maintains the ability to bind to an antigen. Examples of antigen-binding fragments include Fab, Fab', F(ab'), 2 , Fv, scFv (single-chain Fv), diabody, sc(Fv) 2 (Single chain (Fv) 2 ). For example, when an antibody is digested with papain, Fab can be obtained. Alternatively, when an antibody is digested with pepsin, F(ab') can be obtained. 2 , and further reducing it can obtain Fab'. Antigen-binding fragments of other antibodies can also be prepared by methods known to those skilled in the art. In the present invention, such antigen-binding fragments of antibodies can be used.
[0050] In the present invention, the antibody that binds to insoluble fibrin is an antibody that binds to insoluble fibrin with a stronger affinity than that to fibrinogen (i.e., with a lower dissociation constant K than that to fibrinogen). D The antibody that binds to insoluble fibrin with a stronger affinity than that to fibrinogen may be, for example, an antibody that binds to a peptide consisting of the amino acid sequence described in SEQ ID NO: 17 or 18 (see WO2014 / 133093). The amino acid sequence described in SEQ ID NO: 17 corresponds to the amino acid sequence described in SEQ ID NO: 1 of WO2014 / 133093, and the amino acid sequence described in SEQ ID NO: 18 corresponds to the amino acid sequence described in SEQ ID NO: 2 of WO2014 / 133093.
[0051] Examples of antibodies or antigen-binding fragments thereof that bind to insoluble fibrin with an affinity stronger than that to fibrinogen include antibodies or antigen-binding fragments thereof that have heavy chain CDR1 to 3 and light chain CDR1 to 3 of an antibody selected from the group consisting of the 10-102 antibody, 34-105 antibody, and Fib-0355 antibody disclosed in WO2014 / 133093 as corresponding CDRs.
[0052] As antibodies or antigen-binding fragments thereof that bind to insoluble fibrin with an affinity stronger than that to fibrinogen, for example, antibodies or antigen-binding fragments thereof having heavy chain CDR1 to 3 and light chain CDR1 to 3 of an antibody selected from the group consisting of the 99 antibody, 1101 antibody and 0211 antibody disclosed in WO2018 / 203517 as corresponding CDRs can also be mentioned.
[0053] As antibodies or antigen-binding fragments thereof that bind to insoluble fibrin with an affinity stronger than that for fibrinogen, further examples include antibodies or antigen-binding fragments thereof that contain: a heavy chain variable region comprising a heavy chain CDR1 having an amino acid sequence described in SEQ ID NO: 1, a heavy chain CDR2 having an amino acid sequence described in SEQ ID NO: 2, and a heavy chain CDR3 having an amino acid sequence described in SEQ ID NO: 3, and a light chain variable region comprising a light chain CDR1 having an amino acid sequence described in SEQ ID NO: 4, a light chain CDR2 having an amino acid sequence described in SEQ ID NO: 5, and a light chain CDR3 having an amino acid sequence described in SEQ ID NO: 6. The antibody may be a human chimeric antibody or a humanized antibody. According to the present invention, a humanized antibody having the above-mentioned heavy chain variable region and light chain variable region can also be provided.
[0054] As antibodies or antigen-binding fragments thereof that bind to insoluble fibrin with an affinity stronger than that for fibrinogen, for example, antibodies or antigen-binding fragments thereof that contain: a heavy chain variable region having an amino acid sequence of the amino acid sequence described in SEQ ID NO: 7 and a light chain variable region having an amino acid sequence of the amino acid sequence described in SEQ ID NO: 8. In addition to the heavy chain variable region, the antibody may further contain a heavy chain constant region or a portion thereof in a Fab fragment. The antibody may be a human chimeric antibody or a humanized antibody. According to the present invention, a humanized antibody having the above-mentioned heavy chain variable region and light chain variable region may also be provided.
[0055] As antibodies or antigen-binding fragments thereof that bind to insoluble fibrin with an affinity stronger than that for fibrinogen, further examples include antibodies or antigen-binding fragments thereof that contain: a heavy chain variable region comprising a heavy chain CDR1 having an amino acid sequence described in SEQ ID NO: 9, a heavy chain CDR2 having an amino acid sequence described in SEQ ID NO: 10, and a heavy chain CDR3 having an amino acid sequence described in SEQ ID NO: 11, and a light chain variable region comprising a light chain CDR1 having an amino acid sequence described in SEQ ID NO: 12, a light chain CDR2 having an amino acid sequence described in SEQ ID NO: 13, and a light chain CDR3 having an amino acid sequence described in SEQ ID NO: 14. The antibody may be a human chimeric antibody or a humanized antibody. According to the present invention, a humanized antibody having the above-mentioned heavy chain variable region and light chain variable region can also be provided.
[0056] As antibodies or antigen-binding fragments thereof that bind to insoluble fibrin with an affinity stronger than that for fibrinogen, for example, antibodies or antigen-binding fragments thereof that contain: a heavy chain variable region having an amino acid sequence of the amino acid sequence described in SEQ ID NO: 15, and a light chain variable region having an amino acid sequence of the amino acid sequence described in SEQ ID NO: 16. In addition to the heavy chain variable region, the antibody may further contain a heavy chain constant region or a portion thereof in a Fab fragment. The antibody may be a human chimeric antibody or a humanized antibody. According to the present invention, a humanized antibody having the above-mentioned heavy chain variable region and light chain variable region may also be provided.
[0057] According to the present invention, there is also provided an antibody that competes with the antibody described in (3) above for binding to insoluble fibrin, and preferably an antibody that competes with the antibody. Here, the antibody is preferably a humanized antibody.
[0058] According to the present invention, there is also provided an antibody that competes with the antibody described in (4) above for binding to insoluble fibrin, or preferably an antibody that competes with the antibody. Here, the antibody is preferably a humanized antibody.
[0059] According to the present invention, the antibody described in (1) above is a humanized antibody, and may be an insoluble fibrin-specific antibody.
[0060] According to the present invention, the antibody described in (2) above is a humanized antibody, and may be an insoluble fibrin-specific antibody.
[0061] According to the present invention, the antibody described in (3) above is a humanized antibody, and may be an insoluble fibrin-specific antibody.
[0062] According to the present invention, the antibody described in (4) above is a humanized antibody, and may be an insoluble fibrin-specific antibody.
[0063] According to the present invention, the antibody that competes with the antibody described in (3) above for binding to insoluble fibrin, and preferably the antibodies that compete with each other, is a humanized antibody, and may be an insoluble fibrin-specific antibody.
[0064] According to the present invention, the antibody that competes with the antibody described in (4) above for binding to insoluble fibrin, and preferably the antibodies that compete with each other, is a humanized antibody, and may be an insoluble fibrin-specific antibody.
[0065] The antibody of the present invention can bind to a peptide consisting of the amino acid sequence recorded in sequence number 17. Here, the antibody of the present invention can be a humanized antibody. The antibody of the present invention is a humanized antibody that can bind to a peptide consisting of the amino acid sequence recorded in sequence number 17, and can be selected from any of the above antibodies. The antibody of the present invention is a humanized antibody that can bind to a peptide consisting of the amino acid sequence recorded in sequence number 17, and can have 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, or 95% or more amino acid identity with the above antibody in the heavy chain or light chain variable region. The antibody of the present invention is a humanized antibody that can bind to a peptide consisting of the amino acid sequence recorded in sequence number 17, and can be an antibody that has an insertion, deletion, substitution, or addition of 1 amino acid in the heavy chain or light chain variable region with the above antibody. The antibody of the present invention is a humanized antibody that can bind to a peptide consisting of the amino acid sequence recorded in sequence number 17, and can be an antibody that has an insertion, deletion, substitution, or addition of 2 amino acids in the heavy chain or light chain variable region with the above antibody.
[0066] The antibodies of the present invention can be used as the antibody part in antibody-drug conjugates.
[0067] In the present invention, in the antibody-drug conjugate, the antibody and the cytotoxic agent are connected by a linker. Examples of cytotoxic agents include chemotherapeutic drugs (e.g., commercially available anticancer agents such as auristatins (auristatin E, auristatin F phenylenediamine (AFP), monomethyl auristatin E, monomethyl auristatin F and their derivatives), maytansine DM1 and DM4 and their derivatives), camptothecins (SN-38, irinotecan, lortotecan, DB67, BMP1350, ST1481, CKD602, topotecan and exitecan, and their derivatives), DNA minor groove binders (enediynes, lexitropsin, duocarmycins and their derivatives), taxanes (paclitaxel and docetaxel and their derivatives), polyketides (spongiolide and its derivatives), anthraquinones (mitoxantrone and its derivatives), benzodiazepines. Pyrrolobenzodiazepines Indolinium benzodiazepine and Azoline benzodiazepine and their derivatives), vinca alkaloids (vincristine, vinblastine, vindesine and vinorelbine and their derivatives), doxorubicins (doxorubicin, morpholino-doxorubicin and cyanomorpholino-doxorubicin and their derivatives), cardiac glycosides (digitoxin and its derivatives), calicheamicin, epothilones, scutellarin, cemadotine, cemadotine, rhizobactin, fusobactin, compretin, eleutherobin, etoposide, T67 (チュラリク) and nocodazole), radioactive isotopes (e.g. 32 P. 60 C. 90 Y. 111 In, 131 I. 125 I. 153 Sm, 186 Re, 188 Re and 212 Bi) and toxins (e.g., diphtheria toxin A, Pseudomonas endotoxin, ricin, saporin, etc.) can be used as cytotoxic agents in the ADC of the present invention. As the cytotoxic agent in the ADC of the present invention, for example, camptothecin, particularly SN-38 or exotecan can be preferably used. Any cytotoxic agent used for treating cancer can be used as the cytotoxic agent. As the cytotoxic agent, a pharmaceutically acceptable salt, solvate (e.g., hydrate), ester or prodrug of the above-mentioned cytotoxic agent can also be used.
[0068] In the present invention, the ADC can be connected to the antibody and the cytotoxic agent via a linker. In the present invention, the linker can be a non-cleavable linker or a cleavable linker. It is known that the linker structures used in conventional ADCs are various, and they can be used appropriately.
[0069] In one embodiment of the present invention, the joint of ADC includes a plasmin cleavage sequence, which can be cleaved in the presence of plasmin. In the present invention, the position other than the plasmin cleavage sequence of the joint of ADC includes a stable chemical bond in the process of being delivered to insoluble fibrin after administration. By setting it as such a structure, the ADC of the present invention is stable until being delivered to insoluble fibrin after administration, and is cleaved by plasmin after being combined with insoluble fibrin and releases cytotoxic agent only near insoluble fibrin. The plasmin cleavage sequence is an amino acid sequence, specifically a peptide chain including an amino acid sequence such as a plasmin cleavage sequence in the group consisting of valine-leucine-lysine, glycine-proline-lysine, glutamic acid-lysine-lysine, lysine-phenylalanine-lysine, norvaline-chlorohexylalanyl-lysine and norleucine-hexahydrotyrosine-lysine. Such a joint can be appropriately selected and synthesized by those skilled in the art in the preparation of ADC. In one embodiment, the linker can be, for example, a first spacer introduced between the antibody and the plasmin cleavage sequence, for example, polyethylene glycol (PEG), for example, PEG having a repeating unit of about 5 to 40 per molecule, can be used as the first spacer. A second spacer can be introduced between the plasmin cleavage sequence and the cytotoxic agent, for example, p-aminobenzyloxycarbonyl (PABC) can be used as the second spacer.
[0070] In one embodiment, the linker comprises a first spacer and a plasmin cleavage sequence. In one embodiment, the linker comprises a first spacer, a plasmin cleavage sequence, and a second spacer. In certain specific embodiments, the linker comprises PEG, a plasmin cleavage sequence, and PABC.
[0071] In one aspect, the linker does not contain a cleavable moiety other than a plasmin cleavage sequence.
[0072] Regarding the binding of the antibody to the linker, for example, the linker can be linked to the thiol group of the antibody using a maleimide group.
[0073] In one embodiment, the antibody is linked to the anticancer agent via a linker having a maleimide-PEG-plasmin cleavage sequence using its thiol group. In one embodiment, the antibody is linked to the anticancer agent via a linker having a maleimide-PEG-plasmin cleavage sequence-PABC using its thiol group.
[0074] In either case, in the ADC of the present invention, the anticancer agent is connected to the anticancer agent through a linker having a plasmin cleavage site that can be cleaved by plasmin, and when the ADC reaches the position where insoluble fibrin is accumulated, the linker is cleaved by the plasmin present around it at the plasmin cleavage site, and the anticancer agent is released around the insoluble fibrin. It is generally believed that there are multiple locations around cancer tissue where insoluble fibrin is accumulated due to bleeding caused by cancer infiltration (see Figure 8 of WO2018 / 203517), and the antibody of the present invention (i.e., an insoluble fibrin-specific antibody) is useful for targeting cancer in a drug delivery system, and the ADC of the present invention is considered to be useful as a therapeutic drug for cancer.
[0075] The cancer to be treated by the ADC or the pharmaceutical composition of the present invention is not particularly limited, and examples thereof include cancers such as lung cancer, pancreatic cancer, head and neck cancer, prostate cancer, bladder cancer, breast cancer, esophageal cancer, gastric cancer, colon cancer, uterine cancer, ovarian cancer, skin cancer, thyroid cancer, thymic cancer, kidney cancer, testicular cancer, penile cancer, liver cancer, bile duct cancer, brain tumor, bone and soft tissue tumor, retroperitoneal tumor, vascular / lymphangiosarcoma, and metastatic cancers thereof.
[0076] As the object of the present invention, it can be an object that does not suffer from thrombotic injury or a disease accompanied by thrombotic injury, or an object that has not been diagnosed with thrombotic injury or a disease accompanied by thrombotic injury. Thus, it can be expected to reduce the side effects in tissues other than cancerous tissues. Therefore, it can be confirmed whether the object with cancer suffers from thrombotic injury or a disease accompanied by thrombotic injury, and then the ADC of the present invention is administered to the object that does not suffer from thrombotic injury or a disease accompanied by thrombotic injury. Whether or not thrombotic injury or a disease accompanied by thrombotic injury is suffered can be appropriately judged by a doctor.
[0077] In one embodiment of the present invention, the pharmaceutical composition comprises the ADC of the present invention and an excipient. The pharmaceutical composition of the present invention can be administered by intravenous administration, subcutaneous administration, intratumoral administration, intraperitoneal administration, intracerebroventricular administration, intramuscular administration, and the like. The dosage can be appropriately determined by the doctor considering the patient's age, sex, weight, severity of the disease, and the like.
[0078] The ADC of the present invention targets insoluble fibrin accumulated in the stroma of these cancers, causing the cytotoxic agent to accumulate at the target site, and furthermore, has a linker that can be cleaved by plasmin activated at the site where the insoluble fibrin exists, thereby releasing the cytotoxic agent at the target site. Thus, the cancer around the released site can be killed site-specifically.
[0079] According to the present invention, the use of an insoluble fibrin-specific antibody in the manufacture of a drug for treating cancer can be provided. According to the present invention, the use of an ADC in the manufacture of a drug for treating cancer can be provided, wherein the ADC is an ADC of an insoluble fibrin-specific antibody and a cytotoxic agent, and has a plasmin cleavage site where the antibody and the cytotoxic agent can be cleaved by plasmin.
[0080] According to the present invention, a method for treating cancer in a subject in need thereof may be provided, comprising administering a therapeutically effective amount of the ADC of the present invention to the subject. According to the present invention, a method for treating cancer in a subject in need thereof may be provided, comprising: determining whether a subject suffering from cancer suffers from thrombotic injury or a disease accompanied by thrombotic injury, and then administering a therapeutically effective amount of the ADC of the present invention to a subject not suffering from thrombotic injury or a disease accompanied by thrombotic injury.
[0081] According to the present invention, use of the ADC of the present invention in a method for treating cancer may be provided.
[0082] According to the present invention, the antibody of the present invention can be prepared by methods known to those skilled in the art. For example, the antibody of the present invention can be expressed in cells (insect cells, avian cells, Escherichia coli, yeast and mammalian cells), preferably mammalian cells (e.g., cells suitable for protein expression, such as Chinese hamster ovary cells (CHO cells) and 293 cells and their derivatives, such as mammalian cells suitable for protein expression). Expression can be performed, for example, using an expression vector, which contains a nucleic acid encoding the fusion protein of the present invention that is functionally connected to a promoter that can be driven in the expression cell. In the case where the fusion protein requires a light chain, the light chain can be co-expressed in the expression cell. According to the present invention, the fusion protein of the present invention can be purified by a purification method known to those skilled in the art. Purification can be performed using an affinity column containing an antigen, an affinity column for a tag carried by the fusion protein, etc.
[0083] According to the present invention, compositions and pharmaceutical compositions comprising the antibody of the present invention or its antigen-binding fragment can be provided. The pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable excipient in addition to comprising the antibody of the present invention or its antigen-binding fragment. As pharmaceutically acceptable excipients, salts, isotonic agents, pH adjusting agents and water etc. can be cited. In one embodiment, the pharmaceutical composition of the present invention can be a kit (i.e., a ready-to-use kit) comprising a freeze-dried pharmaceutical composition and water for injection.
[0084] The pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of the present invention can be administered by non-oral administration (e.g., intravenous administration). In addition, when the pharmaceutical composition of the present invention is used for intravenous administration, it can be a preparation suitable for intravenous administration. Such a pharmaceutical composition can be appropriately prepared by those skilled in the art. For example, it can be prepared in the same manner as a protein preparation or an antibody preparation. The dosage, timing of administration, and route of administration, etc. can be appropriately determined by a doctor.
[0085] The pharmaceutical composition of the present invention may contain a therapeutically effective amount of an antibody or an antigen-binding fragment thereof.
[0086] In one embodiment of the present invention, the antibody can be linked to a detectable label for in vivo imaging. The detectable label includes, for example, 177 Lu, 111 indium, 67 Cu, 18 F. 99m Tc, 124 I. 125 I and 131 The detectable label may be a positron emission tomography (PET) agent, which includes 124 I. 89 In a specific embodiment, the first antibody and / or the second antibody or the antigen-binding portion or derivative thereof is radiolabeled. The radiolabeling may be 177 Lu, 111 indium, 67 Cu, 18 F. 99m Tc, 124 I. 125 I. 131 I and 99m At least one of Tc.
[0087] The detectable label can be any label suitable for in vitro and / or in vivo imaging. Imaging can include any one or more of the following: planar radionuclide imaging, positron emission tomography (PET), echo planar imaging (EPI), single photon emission computed tomography (SPECT), ultrasound imaging (e.g., non-radioactive, contrast-specific, high frequency, two-dimensional), magnetic resonance imaging (MRI; also known as magnetic resonance tomography or MRT), X-ray, computed tomography (CT), fluorescence imaging, near-infrared imaging, and other imaging methods useful or available in medicine. Therefore, these contrast agents, imaging agents suitable for these can be linked to antibodies.
[0088] According to the present invention, there are provided the antibody of the present invention linked to a detectable label for in vivo imaging, and a diagnostic drug or diagnostic kit containing the antibody.
[0089] According to the present invention, there can be provided a method for observing fibrin in a subject, comprising administering to the subject an effective amount of the antibody of the present invention linked to a detectable label for in vivo imaging.
[0090] Example
[0091] Example 1: Preparation of humanized 1101 antibody and humanized 99 antibody
[0092] The antibody produced by clone 1101 described in WO2018 / 203517 (antibody 1101) and the monoclonal antibody produced by clone 99 (antibody 99) were humanized to obtain humanized antibody 1101 and humanized antibody 99, respectively. During humanization, the sequence of the CDR is changed to improve the binding affinity to insoluble fibrin.
[0093] Using the obtained humanized 1101 antibody and humanized 99 antibody, the binding to insoluble fibrin was confirmed by ELISA experiment. Prepare ELISA coated with bovine serum albumin (BSA), fibrinogen (FNG), soluble fibrin (SF), fibrinolysis product (FDP) and insoluble fibrin (IF). Block the surface of the ELISA plate with TBS-T containing 1% BSA and 0.05% Tween 20, add HRP-labeled humanized 1101 antibody and HRP-labeled humanized 99 antibody, and react them. Add TMB reagent as HRP substrate to develop color, and use an enzyme reader (SpectraMax Paradigm, molecular Device) to detect the color. The results of color intensity are shown in Figure 1 .like Figure 1 As shown, both humanized 99 antibody and humanized 1101 antibody specifically bind to insoluble fibrin.
[0094] Then, the binding of humanized 1101 antibody and humanized 99 antibody to denatured fibrinogen was confirmed by Western blotting. The fibrinogen solution was diluted with a loading buffer containing 2-mercaptoethanol and SDS, and heated at 95°C to obtain denatured fibrinogen. The obtained denatured fibrinogen was subjected to SDS-PAGE, transferred to a PVDF filter, and then filtered using StartingBlock. TM(TBS) blocking buffer (Thermo Fisher). Then, humanized 1101 antibody and humanized 99 antibody are reacted with the filter membrane. In denatured fibrinogen, the sites specifically exposed in the insoluble fibrin to which humanized 1101 antibody and humanized 99 antibody bind are exposed in the same way as insoluble fibrin, and therefore can bind to humanized 1101 antibody and humanized 99 antibody. The filter membrane is washed and blocked, and then protein blotting is performed using HRP-labeled anti-human IgG antibody (Bethyl) as a secondary antibody and ECL (trademark) Prime Western Blotting Detection Reagent (Thermo Fisher) as a luminescent reagent. Photography and image analysis are performed using the ChemiDoc imaging system (Bio-rad). The results are as shown in the figure. Figure 2 As shown, both humanized 1101 antibody and humanized 99 antibody were able to detect denatured fibrin at a concentration of 0.04 μg / mL.
[0095] We then attempted to use humanized 1101 antibody and humanized 99 antibody for immunohistochemical staining (IHC staining). Pancreatic tissue sections of pancreatic cancer model mice (HE-PKC mice) were fixed with paraformaldehyde according to conventional methods to prepare sections. The sections were blocked with PBS containing 1% BSA, and humanized 1101 antibody and humanized 99 antibody (10 mg or 1 mg) were allowed to react with the obtained tissue sections. The sections were stained using Alexa 647-labeled anti-human IgG (Jackson Immunotechnology) as a secondary antibody and DAPI as a nuclear staining reagent. Virtual Slices (Olympus Life Sciences) were used to photograph the sections, and OlyVIA was used for image analysis. The results are as follows. Figure 3 As shown. Figure 3 As shown, the obtained humanized 1101 antibody and humanized 99 antibody are useful in IHC staining.
[0096] In addition, thrombi were found in the blood vessels of normal tissues of human lung cancer resection specimens. Immunohistochemical staining was performed on the thrombi using humanized 1101 antibody and humanized 99 antibody in the same manner as above. Figure 4 As shown. Figure 4 As shown, humanized 1101 antibody and humanized 99 antibody can respectively visualize the thrombus site. In other words, it is also shown that humanized 1101 antibody and humanized 99 antibody bind to human thrombus.
[0097] Then, recombinant CHO cells expressing humanized 99 antibody and humanized 1101 antibody were prepared. The particle size (nm) of the produced humanized 1101 antibody and humanized 99 antibody was measured using Delsa (trademark) Nano HC (Beckman coulter). The results are shown in Figure 5 As shown. Figure 5 As shown, the humanized 1101 antibody and the humanized 99 antibody showed monodisperse particle size distribution, and the particle size of the humanized 1101 antibody was more uniform.
[0098] Sequence Listing
[0099] SEQ ID NO: 1: Amino acid sequence of heavy chain CDR1 of humanized anti-fibrin antibody 1101 clone
[0100] SEQ ID NO: 2: Amino acid sequence of heavy chain CDR2 of humanized anti-fibrin antibody 1101 clone
[0101] SEQ ID NO: 3: Amino acid sequence of heavy chain CDR3 of humanized anti-fibrin antibody 1101 clone
[0102] SEQ ID NO: 4: Amino acid sequence of light chain CDR1 of humanized anti-fibrin antibody 1101 clone
[0103] SEQ ID NO: 5: Amino acid sequence of light chain CDR2 of humanized anti-fibrin antibody 1101 clone
[0104] SEQ ID NO: 6: Amino acid sequence of light chain CDR3 of humanized anti-fibrin antibody 1101 clone
[0105] SEQ ID NO: 7: Amino acid sequence of the heavy chain variable region of anti-fibrin antibody 1101 clone
[0106] SEQ ID NO: 8: Amino acid sequence of the light chain variable region of anti-fibrin antibody 1101 clone
[0107] SEQ ID NO: 9: Amino acid sequence of heavy chain CDR1 of humanized anti-fibrin antibody clone 99
[0108] SEQ ID NO: 10: Amino acid sequence of heavy chain CDR2 of humanized anti-fibrin antibody clone 99
[0109] SEQ ID NO: 11: Amino acid sequence of heavy chain CDR3 of humanized anti-fibrin antibody clone 99
[0110] SEQ ID NO: 12: Amino acid sequence of light chain CDR1 of humanized anti-fibrin antibody clone 99
[0111] SEQ ID NO: 13: Amino acid sequence of light chain CDR2 of humanized anti-fibrin antibody clone 99
[0112] SEQ ID NO: 14: Amino acid sequence of light chain CDR3 of humanized anti-fibrin antibody clone 99
[0113] SEQ ID NO: 15: Amino acid sequence of the heavy chain variable region of humanized anti-fibrin antibody clone 99
[0114] SEQ ID NO: 16: Amino acid sequence of the light chain variable region of humanized anti-fibrin antibody clone 99
[0115] SEQ ID NO: 17: An example of an amino acid sequence exposed in insoluble fibrin (β chain)
[0116] SEQ ID NO: 18: An example of an amino acid sequence exposed in insoluble fibrin (γ chain)
Claims
1. An antibody or antigen-binding fragment thereof that binds to insoluble fibrin, comprising: (1) a heavy chain variable region comprising a heavy chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 1, a heavy chain CDR2 consisting of the amino acid sequence set forth in SEQ ID NO: 2, and a heavy chain CDR3 consisting of the amino acid sequence set forth in SEQ ID NO: 3, and A light chain variable region comprising a light chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 4, a light chain CDR2 consisting of the amino acid sequence set forth in SEQ ID NO: 5, and a light chain CDR3 consisting of the amino acid sequence set forth in SEQ ID NO: 6; or (2) a heavy chain variable region comprising a heavy chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 9, a heavy chain CDR2 consisting of the amino acid sequence set forth in SEQ ID NO: 10, and a heavy chain CDR3 consisting of the amino acid sequence set forth in SEQ ID NO: 11, and a light chain variable region comprising a light chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 12, a light chain CDR2 consisting of the amino acid sequence set forth in SEQ ID NO: 13, and a light chain CDR3 consisting of the amino acid sequence set forth in SEQ ID NO: 14, Furthermore, the antibody or antigen-binding fragment thereof that binds to insoluble fibrin is a humanized antibody or antigen-binding fragment thereof.
2. An antibody-drug conjugate comprising the antibody or antigen-binding fragment thereof according to claim 1.
3. A pharmaceutical composition comprising the antibody-drug conjugate according to claim 2.
Citation Information
Patent Citations
Antibody against insoluble fibrin
WO2014133093A1
Plasmin-cleavable Anti-insoluble fibrin antibody-drug conjugate
WO2018203517A1
Plasmin-cleavable Anti-insoluble fibrin antibody-drug conjugate
EP3620471A1
Antibody against insoluble fibrin
US20160011217A1
Novel antifibrin antibody
WO2011158973A1
